Trial Profile

KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KB 707 (Primary) ; Pembrolizumab
Indications Lung cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions
Acronyms KYANITE-1
Sponsors Krystal Biotech

Most Recent Events

06 May 2025 According to a Krystal Biotech media release, company will present data from this study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting next month.
24 Apr 2025 According to a Krystal Biotech media release, company will present data from this study at American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting.
07 Feb 2025 Planned number of patients changed from 140 to 200.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com